Agustín Seoane

Agustín Seoane

Auto-generated profile, based on publicly available information

Agustín Seoane

Department of Digestive Diseases, Hospital del Mar, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
Rodrigo JoverRodrigo Jover
Rodrigo Jover
Pedro ZapaterPedro Zapater
Pedro Zapater
EPEduardo Polanía
Eduardo Polanía
Luis BujandaLuis Bujanda
Luis Bujanda
ALAngel Lanas
Angel Lanas
ACAntoni Castells
Antoni Castells

21 March 2012 in Endoscopy
Verified
Journal Article
Closed access
PDF file
RJR. Jover
R. Jover
MHM. Herráiz
M. Herráiz
OAO. Alarcón
O. Alarcón
EBE. Brullet
E. Brullet
Luis BujandaLuis Bujanda
Luis Bujanda
ESE. Vázquez Sequeiros
E. Vázquez Sequeiros
Collecting the evidence about the quality of colonoscopy screening for colorectal cancer (CRC) in order to serve as a tool for screening programs, endoscopy units and endoscopists that perform screening colonoscopies. Defining and establishing quality indicators and minimum requirements based on available evidence that endoscopy units and endoscopists involved in CRC screening programs should meet. Providing evidence about procedures that may improve the quality of colonoscopy.

1 October 2006 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
ASAntonio Salar
Antonio Salar
NJNuria Juanpere
Nuria Juanpere
BBBeatriz Bellosillo
Beatriz Bellosillo
EDEva Domingo-Domenech
Eva Domingo-Domenech
BEBlanca Espinet
Blanca Espinet
SSSergio Serrano
Sergio Serrano
The frequency of gastrointestinal (GI) tract involvement in mantle cell lymphoma (MCL) at diagnosis is reported to be below 30%. To investigate the actual frequency of GI involvement by MCL, upper and lower endoscopy was prospectively performed on 13 untreated MCL patients at diagnosis. Multiple biopsies from endoscopically normal and abnormal gastric and colonic mucosa were studied with immunohistochemistry (IHC) for CD20, CD5, and cyclin D1, as well as fluorescence in situ hybridization (FISH) for t(11;14) and polymerase chain reaction (PCR) for immunoglobulin heavy chain gene. Abnormal mucosa was identified in 38% of cases by upper endoscopy (mainly mild nonspecific gastritis) and in 54% of cases by lower endoscopy (mostly micropolyps). Histologically, infiltration by MCL was demonstrated in the stomach in 77% of cases and in the colon in 77% of cases. As a whole, 92% of patients showed upper or lower GI tract infiltration by MCL. Histologic evidence of MCL involvement was present in all cases with endoscopically abnormal mucosa, but it was also observed in two-thirds of cases with endoscopically unremarkable mucosa. Positive cyclin D1 IHC was seen in all instances displaying CD20 and CD5-positive lymphoid infiltrates, whereas t(11;14) was demonstrated by FISH in 63.5% and PCR was clonal in 64% of those instances. In conclusion, the great majority of MCL patients showed GI tract involvement at the time of diagnosis, not uncommonly in the form of minute lymphoid infiltrates. IHC for cyclin D1 was significantly more sensitive than FISH t(11;14) or PCR for immunoglobulin heavy chain gene to confirm MCL in this setting.

1 January 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
IPIgnasi Puig
Ignasi Puig
MLMaría López-Cerón
María López-Cerón
AAAnna Arnau
Anna Arnau
ÒRÒria Rosiñol
Òria Rosiñol
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
NANadia Ascon
Nadia Ascon

4 February 2016 in Endoscopy
Verified
Journal Article
Closed access
PDF file
RJRodrigo Jover
Rodrigo Jover
Pedro ZapaterPedro Zapater
Pedro Zapater
LBLuis Bujanda
Luis Bujanda
VHVicent Hernandez
Vicent Hernandez
Joaquin CubiellaJoaquin Cubiella
Joaquin Cubiella
NUNull
Null
Background and study aim: Several factors have been shown to be related to colonoscopy quality; however, little is known about the effects of endoscopist factors. This study analyzed the influence of endoscopist-related characteristics on quality indicators for colonoscopy. Patients and methods: The study included 48 endoscopists who each performed at least 20 colonoscopies in the colonoscopy arm of a randomized controlled trial comparing fecal immunochemical test vs. colonoscopy in colorectal cancer screening. These endoscopists performed a total of 3838 procedures in the trial. The following were calculated for each endoscopist: adenoma detection rate (ADR), advanced ADR, proximal ADR, distal ADR, and adenoma per colonoscopy rate (APCR). The characteristics of endoscopists were assessed with regard to colonoscopy quality using multivariate regression analysis. Endoscopist characteristics included age, sex, exclusive endoscopy practice, years as a physician, years as a specialist, specialty, total (life-long) number of colonoscopies performed, annual colonoscopy volume, number of hours/week dedicated to endoscopy and number of educational activities in the previous year. Results: Factors associated with ADR were age of the endoscopist (odds ratio [OR] 1.11, 95 % confidence interval [CI] 1.01 – 1.21; P = 0.01) and life-long number of colonoscopies (OR 1.06, 95 %CI 1.01 – 1.11; P = 0.01). Only exclusive dedication to endoscopy practice was found to be independently related to proximal ADR (OR 1.71, 95 %CI 1.15 – 2.74; P = 0.001). Life-long number of colonoscopies was independently related to detection of distal adenomas (OR 1.07, 95 %CI 1.01 – 1.13; P = 0.01). None of the analyzed endoscopist characteristics was associated with advanced ADR or APCR. Conclusions: This study found that the experience of the endoscopist and exclusive dedication to endoscopy practice, but not annual colonoscopy volume, were associated with better colonoscopy quality.

4 August 2016 in Endoscopy
Verified
Journal Article
Open access
PDF file
MÁMarco Antonio Álvarez-González
Marco Antonio Álvarez-González
JRJuana A. Flores-Le Roux
Juana A. Flores-Le Roux
ASAgustin Seoane
Agustin Seoane
JPJuan Pedro-Botet
Juan Pedro-Botet
LCLaura Carot
Laura Carot
VLVicente Lorenzo-Zuniga
Vicente Lorenzo-Zuniga
Background and study aims: Previous studies have reported that diabetes mellitus is an independent risk factor for inadequate bowel preparation. Current guidelines do not recommend a specific preparation for this patient population. The aims of this study were to assess the efficacy, safety, and tolerability of an adapted preparation protocol for colon cleansing in patients with type 2 diabetes mellitus. Patients and methods: This randomized, single-blind, parallel group, superiority trial compared a conventional bowel preparation protocol (CBP) with a diabetes-specific preparation protocol (DSP). The CBP included a low-fiber diet for 3 days followed by a clear liquid diet for 24 hours before colonoscopy. The DSP included a multifactorial strategy combining an educational intervention, a low-fiber diet, and adjustment of blood glucose-lowering agents. All patients received 4 L of a polyethylene glycol solution in a split-dose regimen. The endoscopists were blinded to the preparation protocol. The primary outcome measure was inadequate bowel preparation according to the Boston Bowel Preparation Scale. Secondary outcome measures included hypoglycemic events, tolerability, and acceptability. Results: A total of 150 patients were included in the study (74 CBP and 76 DSP). Both groups were comparable in terms of baseline characteristics. Inadequate bowel cleansing was more frequent following CBP than DSP (20 % vs. 7 %, P = 0.014; risk ratio 3.1, 95 % confidence interval 1.2 – 8). Only CBP and performance status were independently associated with inadequate bowel preparation. Both preparations were equally tolerated and accepted by patients, and side-effects were similar between the groups. Conclusions: A multifactorial strategy for bowel preparation in patients with diabetes undergoing colonoscopy showed a threefold reduction in the rate of inadequate bowel preparation, with no differences in safety and tolerability compared with conventional preparation. Trial registration: ClinicalTrials.gov (NCT02300779).